Jiva.ai

Last updated on

Visit website

Check out this poster case study with additional information about what Jiva.ai achieved during their time on the Accelerator programme.

NHS problem

In the UK there are at least 145,000 patients undergoing prostate biopsy annually, amidst a backdrop of 174,000 MRI scans preceding that treatment. With almost 48,000 confirmed diagnoses, there is an enormous cost to mis/overdiagnosis – at least a £100 million per year; that is not including the ongoing treatment cost of complications and litigation. JivaRDX reduces human subjectivity associated with interpretation of Prostate MRIs (misdiagnosis), improves prognosis of prostate cancer patients via earlier and more accurate detection of clinically significant lesions and reduces the number of unwarranted biopsies, which carry a high risk of complications.

The solution

Jiva.ai is the world’s first low code/no code AI platform focusing on multimodality and explainability. This will empower clinicians to rapidly prototype AI (diagnostic, prognostic and treatment) solutions. They have proven the value of this platform approach by building prostate cancer (JivaRDX – clinical investigation stage) and liver disease diagnostics as well as other automation tasks within healthcare. Whilst the immediate use-case is a specific disease vertical (Prostate Cancer), it is the enablement and empowerment of putting AI engineering in the hands of clinicians that is truly at the heart of the company.

Impact

Jiva.ai will allow clinicians and healthcare organisations to rapidly prototype AI (diagnostic, prognostic and treatment) solutions. This will allow for improved outcomes for a variety of diseases in earlier and more accurate diagnostics.

As an example in prostate cancer diagnostics, JivaRDX will have the follow on effects of:

  1. Alleviating requirements for interpretation of medical imaging;
  2. Reducing human error associated with interpretation of MRI’s (misdiagnosis);
  3. Improving prognosis of prostate cancer patients via earlier and more accurate detection of clinically significant prostate cancers;
  4. Reducing the numbers of unwarranted investigations and treatments and possible surgical side effects (life threatening sepsis, UTI, erectile dysfunction, etc) and litigation associated with these;
  5. Reducing requirement for hospital resources (time, HR, cost and equipment).

At a 90% sensitivity, they project it can save the NHS at least £100 million per year and over 16,000 hours of radiology time, which potentially translates to a 34% increase in patient throughput. Where time to diagnosis has been known to extend to 57 days per patient (a situation that will only get worse post-COVID).